Hepatitis B virus/hepatitis C virus upregulate angiopoietin-2 expression through mitogen-activated protein kinase pathway

Hepatology Research

Volumn 40, Issue 10, 2010, Pages 1022-1033

  Li, Yanmei ^a   Chen, Jizheng ^a   Wu, Chunchen ^a   Wang, Linding ^a   Lu, Mengji ^b   Chen, Xinwen ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Angiopoietin 2; AP 1; Ets1; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Mitogen activated protein kinase

Indexed keywords

ANGIOPOIETIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 77957245588     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00712.x     Document Type: Article

References (50)

1. Gurtsevitch VE. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc) 2008, 73:504-13.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999, 353:1253-7.
3. Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007, 33:7-15.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-64.
5. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004, 41:864-80.
6. Holash J, Maisonpierre PC, Compton D. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-8.
7. Salcedo Mora X, Sanz-Cameno P, Medina J. Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev Esp Enferm Dig 2005, 97:699-706.
8. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004, 39:1185-95.
9. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999, 103:341-5.
10. Helfrich I, Edler L, Sucker A. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009, 15:1384-92.
11. Melgar-Lesmes P, Tugues S, Ros J. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats. Gut 2009, 58:285-92.
12. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-9.
13. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-10.
14. Asahara T, Chen D, Takahashi T. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998, 83:233-40.
15. Sanz-Cameno P. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006, 169:1215-22.
16. Gu B, Gates AT, Isken O, Behrens SE, Sarisky RT. Replication studies using genotype 1a subgenomic hepatitis C virus replicons. J Virol 2003, 77:5352-9.
17. Zhong J, Gastaminza P, Chung J. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006, 80:11082-93.
18. Han Q, Xu C, Wu C, Zhu W, Yang R, Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res 2009, 145:63-73.
19. Ye FC. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007, 81:3980-91.
20. Wu J. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009, 49:1132-40.
21. Broering R. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008, 48:914-22.
22. Schaefer S, Glebe D, Wend UC, Oyunbileg J, Gerlich WH. Universal primers for real-time amplification of DNA from all known Orthohepadnavirus species. J Clin Virol 2003, 27:30-7.
23. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009, 27:30-7.
24. Ker CG, Chen HY, Juan CC. Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology 1999, 46:646-50.
25. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009, 50:604-20.
26. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004, 130:307-19.
27. Zeng W. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 2008, 48:1517-27.
28. Tanaka H. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006, 26:543-51.
29. Hasegawa Y, Abe M, Yamazaki T. Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1. Biochem Biophys Res Commun 2004, 316:52-8.
30. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 2004, 24:1803-9.
31. Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008, 217:809-18.
32. Scharte M, Han X, Bertges DJ, Fink MP, Delude RL. Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes in cultured rat enterocytes. Am J Physiol Gastrointest Liver Physiol 2003, 284:G373-84.
33. Jung JO, Gwak GY, Lim YS, Kim CY, Lee HS. [Role of hepatic stellate cells in the angiogenesis of hepatoma]. Korean J Gastroenterol 2003, 42:142-8.
34. Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F, Vandenbunder B. Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 2003, 22:1795-806.
35. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-92.
36. Chen ZB, Shen SQ, Ding YM. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol 2008, 26:365-71.
37. Yang JC. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009, 49:1962-71.
38. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009, 49:1469-82.
39. Street A, Macdonald A, Crowder K, Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004, 279:12232-41.
40. Mannova P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005, 79:8742-9.
41. Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 2005, 79:5006-16.
42. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001, 1:287-96.
43. Kato N. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000, 32:405-12.
44. Yun C, Um HR, Jin YH. NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett 2002, 184:97-104.
45. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996, 70:4978-85.
46. Kanda T, Yokosuka O, Nagao K, Saisho H. State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X. Cancer Lett 2006, 234:143-8.
47. Girard S, Vossman E, Misek DE. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 2004, 40:708-18.
48. Li S. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation. Virology 2009, 391:257-64.
49. Azam F, Koulaouzidis A. Hepatitis B virus and hepatocarcinogenesis. Ann Hepatol 2008, 7:125-9.
50. Nguyen DH, Ludgate L, Hu J. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol 2008, 216:289-94.